10:02 AM EST - Oncolytics Biotech Inc : Announced two abstracts across distinct tumor types were accepted for presentation at the American Association for Cancer Research Annual Meeting 2026, at the San Diego Convention Center from April 17-22, 2026. Pelareorep is an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways via double-stranded RNA signaling, driving interferon production, dendritic cell activation, and cytotoxic T-cell priming. Oncolytics Biotech Inc
shares N.ONCY are trading off $0.01 at $0.95.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7811362759413847
